Abstract
Objective To explore the diagnostic value of serum angiopoietin (Ang), vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) combined with the Chinese medicine antitumor formula in the treatment of advanced renal carcinoma. Methods Retrospective analysis was performed for the data of 60 patients with advanced renal cancer admitted at Yantaishan Hospital from February 2019 to February 2020. All patients were treated with Chinese medicine antitumor formula. The serum Ang, VEGF, and CRP levels in venous blood samples were detected before and after treatment. Sensitivity, specificity, and AUC of combined serum Ang, VEGF, and CRP were analyzed utilizing the receiver operating characteristic curve (ROC) (95% CI). Results There were 52 cases of clear-cell carcinoma (86.7%), 7 cases of papillary carcinoma (11.7%), and 1 case of chromophobe renal cell carcinoma (1.7%). The average tumor diameter was (9.67 ± 0.65) cm, and the KPS score was (74.68 ± 1.52). About 75% of the patients had metastasis. After treatment, the level of serum Ang, VEGF, and CRP was immensely lower compared to that before treatment (P < 0.001). The sensitivity, specificity, and AUC (95%CI) of the combined detection of Ang, VEGF, and CRP before treatment were 86.7%, 90.0%, and 0.883 (0.817–0.950), while the sensitivity, specificity, and AUC (95%CI) of the combined detection of Ang, VEGF, and CRP were 83.3%, 86.7%, and 0.850 (0.776–0.9524), respectively. Conclusion The combined detection of serum Ang, VEGF, and CRP has high diagnostic value for patients with advanced renal cancer treated with Chinese medicine antitumor formula.
Highlights
Renal cancer is a malignant tumor that occurs in the urinary tubule epithelium of the renal parenchyma. e incidence rate of the disease in 2011 was 3.8%
Patients with advanced metastatic renal cancer lack sensitivity to conventional treatments such as radiotherapy and chemotherapy [4]. eir average life expectancy is less than 1 year, and the five-year survival rate is less than 10% [5,6,7], and patients usually have a poor prognosis
Study Design. is retrospective study was conducted at Yantaishan Hospital, Yantai, Shandong, China, from February 2019 to February 2020 to explore the diagnostic value of serum Ang, vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) combined detection in the treatment of advanced renal carcinoma after being treated with the Chinese medicine antitumor formula
Summary
Renal cancer is a malignant tumor that occurs in the urinary tubule epithelium of the renal parenchyma. e incidence rate of the disease in 2011 was 3.8%. Renal cancer is a malignant tumor that occurs in the urinary tubule epithelium of the renal parenchyma. E incidence rate of the disease in 2011 was 3.8%. According to the data of the Ministry of Health of China, its incidence has been increasing year by year in the past ten years and ranks top ten among the highest incidence of male malignant tumors in China [1, 2]. Eir average life expectancy is less than 1 year, and the five-year survival rate is less than 10% [5,6,7], and patients usually have a poor prognosis. Prolonging the survival time of patients with advanced renal cell carcinoma is the focus of clinical research. No optimum remedies for renal cancer have been found at present, and some studies have shown that traditional
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
